How Barie Compares Regulatory Approval Pathways for Medical Devices Across FDA, EU MDR, and UK MHRA

Regulatory Research  ·  Deep Research  ·  FDA · EU MDR · MHRA  ·  Updated April 2026

Three parallel research threads across regulatory frameworks. Official guidance, legislative texts, and recent enforcement actions retrieved from live regulatory sources. A structured comparison covering approval timelines, device classification, documentation requirements, post-market obligations, and enforcement signals — with direct links to each regulatory body for every claim made.

The problem with asking any AI tool about medical device regulation

A regulatory affairs manager at a medical device company asked an AI tool to compare FDA, EU MDR, and MHRA approval requirements before an international market entry strategy meeting. The output was seven paragraphs long and covered the key concepts fluently. It described the CE marking process under the EU MDR, the FDA’s 510(k) and PMA pathways, and the UK’s post-Brexit UKCA marking regime.

The problem emerged when the regulatory team checked the specifics. The EU MDR transition deadlines described in the output reflected the original 2021 implementation schedule. The European Parliament had since extended those deadlines multiple times, most recently through the MDR Corrigendum and the 2024 extension package that gave legacy devices additional time before mandatory MDR compliance. The output presented the original deadlines with no indication they had been revised. A strategy built on those dates would have created a false sense of urgency for some devices and overlooked a genuine compliance window for others.

Medical device regulation does not hold still. The EU MDR transition timeline has changed three times since the original Regulation took effect. The MHRA’s post-Brexit framework continues to evolve with new guidance issued regularly. The FDA publishes updated guidance documents on a rolling basis. Any AI tool answering from training data is describing a regulatory landscape as it existed at an unknown historical point — and in this domain, the difference between last year’s rules and this year’s rules can determine whether a product launch is compliant or not.

Why medical device regulation requires Deep Research and Web Research together: Barie Deep Research retrieves from the official regulatory body websites, the EUR-Lex legislative database, and the FDA’s guidance document portal. Barie Web Research then verifies whether any recent amendments, corrigenda, or Dear Manufacturer letters have been issued since the base legislative texts were published. Both layers run together so the comparison reflects both the statute and the current implementation guidance.

Your prompt

Task prompt: “Compare regulatory approval pathways for medical devices in the US (FDA), EU (MDR), and UK (MHRA).”

One sentence. Three jurisdictions. Barie fires three parallel Deep Research threads, one per regulatory framework, each retrieving the current operative texts, guidance documents, and recent enforcement signals. It then applies a structured comparison framework across five dimensions and delivers the analysis with a source link to the regulatory authority for every claim. Here is the complete workflow.

Step 1: Deep Research fires three simultaneous threads — one per regulatory framework

THREE PARALLEL DEEP RESEARCH THREADS

All three jurisdiction threads begin at the same moment. Barie does not complete the FDA research before starting the EU MDR research. The parallel architecture means the full legislative and guidance dataset for all three frameworks is assembled before any comparative analysis begins. This matters because the comparison is often cross-dimensional — a finding about EU MDR’s post-market surveillance requirements only means something when set against what FDA and MHRA require for the same obligation.

FDA (US) — Sources retrieved

• FDA.gov device guidance database — 510(k), PMA, De Novo pathway documents
• 21 CFR Parts 800–898 — current operative regulations
• FDA enforcement actions database — Warning Letters, recalls
• CDRH recent guidance updates — current year publications

EU MDR — Sources retrieved

• EUR-Lex — Regulation (EU) 2017/745 as amended including corrigenda
• European Commission MDR transition timeline — current deadline schedule
• EUDAMED database status — Notified Body capacity data
• MDR extension packages — 2023 and 2024 amendments operative text

MHRA (UK) — Sources retrieved

• MHRA.gov.uk — UKCA marking requirements and current transition guidance
• UK Medical Devices Regulations 2002 as amended post-Brexit — 
• MHRA Device Bulletin — recent guidance and Dear Manufacturer letters
• Gov.uk — post-Brexit recognition of CE marking current policy

Web Research verifies that no recent amendments have been missed: After the Deep Research database retrieval, Barie Web Research runs a secondary pass across each regulatory body’s recent publications page. This catches guidance documents issued in the weeks before the search that may not yet be fully indexed in the primary databases. For EU MDR specifically, this step has picked up extension corrigenda and Notified Body capacity notices that significantly change the practical compliance picture without being reflected in the base legislative text.

Step 2: The structured comparison across five regulatory dimensions

FIVE-DIMENSION COMPARISON FRAMEWORK

With the full regulatory dataset assembled, Barie applies a five-dimension comparison framework. Each dimension reflects a practical decision point that a regulatory affairs team or market entry strategist needs to understand before committing resources to a jurisdiction. The comparison is not a summary of what the regulation says. It is an analytical assessment of what the regulation requires, how the three frameworks differ from each other on each dimension, and where those differences create risk or opportunity for a device manufacturer.

5 Comparison dimensions  ·  3 Jurisdictions  ·  100% Source-linked  ·  2 Research layers

Dimension 1: Device Classification

🇺🇸 FDA

Three classes: Class I (general controls), Class II (special controls, typically 510(k)), Class III (PMA required). Classification determined by intended use and risk level. Over 1,700 device types with established classifications in the CFR.

[Largest device type library]

Source: FDA CFR 21 Part 862–892

🇪🇺 EU MDR

Four classes: I, IIa, IIb, III. Classification rules apply based on invasiveness, active device status, and intended purpose. MDR reclassified many devices previously under MDD to a higher risk class — a material change for manufacturers transitioning from legacy CE certificates.

[Many reclassifications vs MDD]

Source: EU MDR Annex VIII

🇬🇧 MHRA

Currently mirrors EU classification rules. Post-Brexit UK MDR 2002 amended to reference equivalent classification principles. The MHRA is consulting on whether to diverge from EU classification in future — outcome pending.

[Potential future divergence]

Source: UK MDR 2002 Schedule 2

Dimension 2: Approval Timeline

🇺🇸 FDA

510(k) average review time: 3 to 6 months from acceptance. PMA average total time: 12 to 24 months from submission. De Novo typically 9 to 12 months. FDA publishes real-time performance data on its website.

[Fastest for Class II devices]

Source: FDA CDRH Performance Dashboard

🇪🇺 EU MDR

Notified Body certification for Class IIa and above. Current average: 12 to 24 months for new MDR certificates. Notified Body capacity is severely constrained — fewer than 40 Notified Bodies designated under MDR versus over 80 under MDD. Waitlists are long.

[Capacity bottleneck]

Source: EUDAMED NB Database

🇬🇧 MHRA

UK Approved Bodies (UABs) for Class IIa and above. CE marking still accepted under current MHRA transition policy until defined future date. MHRA is expanding UAB designation capacity. Timeline data is less published than FDA equivalent.

[CE grace period active]

Source: MHRA Medical Devices Guidance

Dimension 3: Documentation Requirements

🇺🇸 FDA

510(k): substantial equivalence predicate analysis, performance testing, labelling. PMA: full clinical data package, manufacturing evidence, risk management. Design History File required under QSR (21 CFR Part 820).

[Predicate-based pathway available]

Source: FDA 510(k) Guidance

🇪🇺 EU MDR

Technical Documentation and Clinical Evaluation Report required for all classes. PMCF plan mandatory. MDR removed the ability to rely on equivalence without a contractual access agreement with the equivalent device manufacturer. This is a significant change versus the old MDD approach.

[Equivalence access restricted]

Source: EU MDR Annex II & III

🇬🇧 MHRA

Technical file requirements broadly equivalent to EU MDR. UK-specific unique device identification (UDI) system being phased in. MHRA has issued its own clinical evaluation guidance which differs in certain respects from the EU MDCG guidance documents.

[UDI phase-in ongoing]

Source: MHRA Technical File Guidance

Dimension 4: Post-Market Obligations

🇺🇸 FDA

Medical Device Reporting (MDR) for adverse events. Malfunction reporting. Annual reports for certain Class III devices. Post-Approval Studies where FDA conditions approval. FDA has been expanding post-market surveillance requirements under FDORA 2022.

[FDORA expanding obligations]

Source: 21 CFR Part 803

🇪🇺 EU MDR

Most extensive post-market framework of the three jurisdictions. Mandatory PMCF for Class IIb and III. Periodic Safety Update Reports (PSUR). Trend reporting. Summary of Safety and Clinical Performance (SSCP) required. All reportable events go through EUDAMED once fully operational.

[Most extensive obligations]

Source: EU MDR Articles 83–100

🇬🇧 MHRA

Adverse event reporting to the MHRA Yellow Card scheme. Field Safety Corrective Actions with MHRA notification. MHRA is building its own post-market database separate from EUDAMED. Requirements broadly similar to EU MDR but UK-specific reporting deadlines differ.

[Separate UK reporting system]

Source: MHRA Adverse Event Reporting

Every comparison cell links to the primary regulatory source: When the EU MDR cell states that equivalence access was restricted under the new regulation, the source link points directly to EU MDR Annex II on EUR-Lex, not to a legal blog summarising what the change means. When the FDA cell references FDORA 2022, the link goes to the FDA’s own guidance page for those requirements. The comparison is grounded in the operative texts, not in secondary commentary that may interpret them differently.

Step 3: Recent enforcement actions retrieved — what regulators are actually actioning right now

LIVE ENFORCEMENT SIGNALS

The comparison framework tells you what the regulation requires. Recent enforcement actions tell you where each regulator is currently concentrating its supervisory attention. Barie Web Research retrieves the most recent enforcement signals from each regulatory body so the comparison reflects not just the rulebook but the current supervisory risk environment.

FDA · CDRH Warning Letter — Q1 2026

QMS non-conformances generating highest Warning Letter volume. FDA CDRH issued 34 Warning Letters in the 12 months to April 2026. The highest volume category was Quality Management System non-conformances under 21 CFR Part 820, particularly design control deficiencies and inadequate CAPA systems. Overseas manufacturers represented 58% of Warning Letter recipients.

Signal: QMS documentation is the active FDA priority

EU MDR · Notified Body Alerts — 2025–2026

PMCF plan deficiencies causing certificate suspension in Class IIb devices. Multiple Notified Bodies issued certificate suspensions for Class IIb devices where the Post-Market Clinical Follow-up plan was assessed as inadequate under the MDR standard. The MDCG published supplementary PMCF guidance in late 2025 to address the interpretation gap, but enforcement action preceded the guidance.

Signal: PMCF is the active EU MDR enforcement priority

MHRA · Field Safety Notices — 2025–2026

Software as a Medical Device classification failures generating MHRA notices. MHRA issued a series of field safety notices for software products marketed as wellness tools that the MHRA assessed as meeting the definition of a medical device under the UK MDR. SaMD classification is an active area of regulatory scrutiny following post-Brexit divergence in software classification guidance.

Signal: SaMD classification is the active MHRA priority

FDA · AI/ML Guidance Update — 2025

FDA issued final guidance on AI/ML-based SaMD — new predetermined change control requirements. FDA published final guidance for AI and machine learning-based software as a medical device in 2025, introducing a predetermined change control plan requirement. This affects any device incorporating adaptive algorithms and represents a new documentation obligation not present in the pre-2025 regulatory landscape for this device type.

Signal: AI/ML SaMD documentation is a new FDA requirement

Step 4: The comparison delivered in formats your regulatory and legal teams use

EXPORT AND DISTRIBUTION

The full comparison exports across the tools your regulatory affairs team uses to act on research. The complete briefing document with all five dimensions, enforcement signals, and linked sources lands in Notion as a structured reference document. A formatted version exports to Google Docs for review by regulatory counsel or for inclusion in a market entry strategy submission. The key enforcement signals for each jurisdiction go to Slack as a digest before the next regulatory review meeting.

Export flow: Notion → Google Docs → Word (.docx) → Slack

For legal teams using HubSpot or Attio to track regulatory submissions and milestones, the timeline data from the comparison is structured into regulatory milestone records aligned to each jurisdiction’s review timeline. A quarterly re-run configured in Barie means the comparison refreshes automatically when new guidance is published, with a Slack alert going to the regulatory team whenever material changes are detected in any of the three frameworks.

Configure quarterly re-runs for a living regulatory intelligence document: Medical device regulation across all three jurisdictions is updated continuously. Each quarterly Barie re-run applies the same Deep Research and Web Research methodology, detects changes in the operative texts or guidance documents, and pushes only the delta to the Notion document. Your regulatory team always has current information without a full repeat research session each time a guidance document is updated.

What you get

A structured comparison of medical device regulatory approval pathways across FDA, EU MDR, and MHRA — covering device classification, approval timelines, documentation requirements, post-market obligations, and recent enforcement signals. Every comparison point linked to the primary regulatory text it came from. Current EU MDR transition deadlines retrieved from the amended regulation, not from pre-amendment sources. MHRA guidance current as of the query date, including the software as a medical device classification signals that are actively generating field safety notices. The comparison delivered to Notion, Google Docs, Word, and Slack in one session.

What it would take a regulatory affairs specialist two days to compile from three sets of regulatory body websites, Barie delivers in one prompt. Every source primary. Every timeline current. Nothing from training data that predates the most recent MDR extension package.

The Verdict

The EU MDR transition timeline has changed three times since the original Regulation entered into force. The FDA’s AI/ML SaMD guidance did not exist before 2025. The MHRA’s post-Brexit software classification position is still being established through field safety notices. A comparison built from training data describes a regulatory landscape that may be partially or entirely superseded by subsequent amendments, guidance documents, and enforcement decisions. Barie Deep Research retrieves from the current operative texts of all three frameworks. Barie Web Research catches the amendments and guidance that postdate those texts. The comparison reflects what regulators actually require today, not what they required at an undisclosed point in the past. In regulatory affairs, that distinction is not a convenience. It is the entire point.

Barie features used in this task

Next steps

→ Barie Deep Research — how live regulatory database retrieval works

→ Web Research — the verification layer that catches recent amendments and guidance updates

→ Prompt Library — regulatory comparison and compliance research templates